Search

Your search keyword '"Sperr, WR"' showing total 431 results

Search Constraints

Start Over You searched for: Author "Sperr, WR" Remove constraint Author: "Sperr, WR"
431 results on '"Sperr, WR"'

Search Results

1. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

3. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

4. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5)

5. Standards and standardization in Mastocytosis: a consensus proposal and report of the year 2005 Working Conference on Mastocytosis

6. The immunoglobulin-like modules C epsilon 3 and alpha 2 are the minimal units necessary for human IgE-Fc epsilon RI interaction

7. Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis

9. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

10. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia

14. Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus.

15. The European competence network on mastocytosis (ECNM)

16. Diagnostic criteria and classification of mastocytosis: a consensus proposal

17. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1

18. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments - Candidates for a novel form of specific immunotherapy

19. Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

20. Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments

22. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.

23. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.

24. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

25. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.

26. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.

27. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM.

28. Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study.

29. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.

30. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis.

31. Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils.

32. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS.

33. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.

34. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT.

35. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.

36. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives.

37. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives.

38. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.

39. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.

40. Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V + systemic mastocytosis: a preclinical study.

41. N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.

42. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.

43. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.

44. Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.

45. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.

46. Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph + Chronic Myeloid Leukemia.

47. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine.

48. Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study.

49. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph + chronic myeloid leukemia.

50. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.

Catalog

Books, media, physical & digital resources